Johnson & Johnson (JNJ) Expected to Release Quarterly Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ) is expected to release its Q3 2026 results before the market opens on Tuesday, October 13th. Analysts expect the company to announce earnings of $2.50 per share and revenue of $25.38 billion for the quarter. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 13, 2026 at 8:30 AM ET.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 earnings per share. On average, analysts expect Johnson & Johnson to post $11.18 EPS for the current fiscal year and $12.33 EPS for the next fiscal year.

Johnson & Johnson Price Performance

JNJ opened at $261.27 on Monday. The company has a market capitalization of $629.64 billion, a price-to-earnings ratio of 30.27, a PEG ratio of 2.65 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $265.83 and a 200-day moving average price of $249.11. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Bank of America reissued a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Guggenheim restated a “buy” rating and set a $287.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), its targeted oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis. Nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with responses sustained and a favorable safety profile. The results strengthen the potential of ICOTYDE as a future growth product and were presented at a dermatology meeting. Johnson & Johnson ICOTYDE two-year psoriasis data
• Positive Sentiment: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. The positive analyst view reflects JNJ’s diversified healthcare portfolio, drug launches and defensive dividend appeal. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several investment commentaries continue to present JNJ as a dividend-focused healthcare holding, emphasizing its long record of dividend growth and relatively dependable cash generation compared with higher-yielding but riskier peers. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report with expectations for continued strength in pharmaceuticals and newer product launches. Investors will focus on revenue growth, guidance and the pace of Stelara-related sales erosion.
• Negative Sentiment: Analysts warn that biosimilar competition for Stelara and challenges in the MedTech business could weigh on near-term growth, limiting the impact of otherwise strong drug performance. J&J stock ahead of Q3 earnings
• Negative Sentiment: Upcoming patent expirations for Imbruvica and Darzalex create a longer-term “patent cliff” risk, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset lost exclusivity. J&J patent cliff analysis
• Negative Sentiment: Boston Scientific has sued JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology device, seeking damages and an injunction. The financial impact is uncertain but adds legal and competitive risk to the MedTech segment. Boston patent lawsuit against J&J subsidiary

Insider Activity

In related news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.